替吉奥单药治疗老年晚期非小细胞肺癌的临床观察

目的观察替吉奥单药治疗老年晚期非小细胞肿瘤（NSCLC）患者的疗效及不良反应。方法对31例II—IB—IV期老年NSCLC患者应用替吉奥（S－1）单药化疗60mg／（m2·d），口服1～14d）21d为1个周期。2个周期后分别按实体瘤疗效评价标准（RECIST）和美国国立癌症研究所（NCI）常见毒性反应标准评价不良反应，同时评估生活质量改善指标。结果本组31例患者中，完全缓解（CR）0例，部分缓解（PR）10例，稳定（sD）13例，进展（PD）8例，有效（CR＋PR）率为：32．3％；临床受益（CR＋PR＋SD）率为：74．2％。中位无疾病进展生存（PFS）期为5．1个月。中位生存（0s）期为7．8个月，1年生存率为30．6％。患者不良反应主要表现为白细胞减少为主的骨髓抑制，白细胞减少I—II度发生率为38．7％（12／31），III—IV度为6．5％（2／31）。血小板减少I—II。发生率为19．3％（6／31），III。为3．2％（1／31）无IV度减少发生。结论采用替吉奥弹药治疗老年晚期NSCLC患者疗效好，不良反应轻，安全，可作为老年晚期NSCLC患者的一线治疗方案。

Clinical study of TS - 1 in treatment of elderly patients with advanced mon- small cell lung cancer

Objective To evaluate the efficacy and toxicity of S1 capsule in the treatment of elderly patients with advanced non - small cell lung cancer（NSCLC）. Methods Totally 31 patients with advanced NSCLC received of TS - 1 capsules orally 60mg/m2 · d on days 1 - 14, rest 7 days for a cycle. Efficacy and toxicities were evaluated at end of every 2 cycles ,according to Evaluation Criteria in Solid Tumors（RECIST） and National Cancer Institute（NCI） common toxicity criteria. Quality of life was evaluated at the same time. Results Complete remission （CR） was not observed, patial remission（PR） was observed in 10 cases,stable disease（SD） was observed in 13 cases and progression disease（PD） was observed in 8 cases. The effective（CR ＋ PR） rate is 32.3 %,and the clinical benefit（CR ＋ PR ＋ SD） rate is 74. 2% , with median progression time of 5.1 months and median survival time of 7.8 months. The main hematologic toxicity included grade III- IV decreasing of white blood cell in 2 cases（6. 5% ） ,grade I - II decreasing of white blood cell in 12 eases（38.7% ） ,grade III decreasing of platelet in 1 cases（3.2% ） ,grade I - II decreasing of platelet in 6 cases （ 19. 3% ）. Conclusions S1 capsule is effective and tolerable in the first - line treatment of elderly patients with ad- vanced NSCLC.